The nuclear hormone receptor PPARγ counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells.

Details

Ressource 1Download: BIB_E427ADEC633E.P001.pdf (5862.87 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_E427ADEC633E
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
The nuclear hormone receptor PPARγ counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells.
Journal
Nature Communications
Author(s)
Woldt E., Terrand J., Mlih M., Matz R.L., Bruban V., Coudane F., Foppolo S., El Asmar Z., Chollet M.E., Ninio E., Bednarczyk A., Thiersé D., Schaeffer C., Van Dorsselaer A., Boudier C., Wahli W., Chambon P., Metzger D., Herz J., Boucher P.
ISSN
2041-1723 (Electronic)
ISSN-L
2041-1723
Publication state
Published
Issued date
2012
Peer-reviewed
Oui
Volume
3
Number
1077
Pages
1-10
Language
english
Notes
Publication types: Journal Article
Abstract
Vascular calcification is a hallmark of advanced atherosclerosis. Here we show that deletion of the nuclear receptor PPARγ in vascular smooth muscle cells of low density lipoprotein receptor (LDLr)-deficient mice fed an atherogenic diet high in cholesterol, accelerates vascular calcification with chondrogenic metaplasia within the lesions. Vascular calcification in the absence of PPARγ requires expression of the transmembrane receptor LDLr-related protein-1 in vascular smooth muscle cells. LDLr-related protein-1 promotes a previously unknown Wnt5a-dependent prochondrogenic pathway. We show that PPARγ protects against vascular calcification by inducing the expression of secreted frizzled-related protein-2, which functions as a Wnt5a antagonist. Targeting this signalling pathway may have clinical implications in the context of common complications of atherosclerosis, including coronary artery calcification and valvular sclerosis.
Pubmed
Web of science
Open Access
Yes
Create date
01/11/2012 19:43
Last modification date
20/08/2019 17:07
Usage data